Vinayak V K, Shandil R K, Bansal V, Singh K, Bhasin D K, Kaur U
Department of Experimental Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
J Med Microbiol. 1990 Jun;32(2):87-91. doi: 10.1099/00222615-32-2-87.
A micro-enzyme linked immunosorbent assay (micro-ELISA) has been evaluated as a diagnostic test to detect amoebic antigen in polyethylene glycol (PEG) precipitated circulating immune complexes (CIC) in sera from patients with amoebiasis. The immune complexes were captured on rabbit anti-amoebic IgG-coated wells of microtitration plates and the complexed antigen was detected by enzyme linked antihuman immunoglobulins. A titre of greater than 160 for the immune complexes was considered to be of clinical significance. The immunoassay detected amoebic, antigen-specific CIC in 35 (94.5%) of 37 patients with confirmed amoebic liver abscess. Twenty (55.5%) of 36 clinically suspected cases of amoebic liver abscess had amoebic antigen-specific CIC and responded favourably to anti-amoebic chemotherapy. Only two (20%) of 10 cases of non-dysenteric symptomatic intestinal amoebic infection had amoebic antigen-specific CIC. One (10%) of 10 patients with non-amoebic intestinal disorders also had amoebic antigen in CIC. However, none of 15 cases of non-amoebic hepatic disorders that included hydatid disease, metastatic adenocarcinoma, hepatocellular carcinoma, cholecystitis and choledocal cyst, 13 cases of rheumatoid arthritis and 25 apparently healthy subjects had amoebic antigen in CIC. The levels of the amoebic antigen-specific CIC did not correlate (p greater than 0.05) with either the number of abscess(es) or lobe(s) of the liver involved. However, the levels of antigen-specific CIC were higher (p less than 0.01) in patients with a liver size of more than 5 cm below the right costal margin. Antigen-specific CIC levels tended to decline or disappear during 3-6 months following completion of therapy.(ABSTRACT TRUNCATED AT 250 WORDS)
一种微量酶联免疫吸附测定法（微量ELISA）已被评估为一种诊断测试，用于检测阿米巴病患者血清中聚乙二醇（PEG）沉淀的循环免疫复合物（CIC）中的阿米巴抗原。免疫复合物被捕获在微量滴定板上包被兔抗阿米巴IgG的孔中，复合抗原通过酶联抗人免疫球蛋白进行检测。免疫复合物滴度大于160被认为具有临床意义。该免疫测定法在37例确诊为阿米巴肝脓肿的患者中检测到35例（94.5%）存在阿米巴抗原特异性CIC。36例临床疑似阿米巴肝脓肿病例中有20例（55.5%）存在阿米巴抗原特异性CIC，且对抗阿米巴化疗反应良好。10例非痢疾性症状性肠道阿米巴感染病例中只有2例（20%）存在阿米巴抗原特异性CIC。10例非阿米巴性肠道疾病患者中有1例（10%）的CIC中也存在阿米巴抗原。然而，15例非阿米巴性肝脏疾病（包括包虫病、转移性腺癌、肝细胞癌、胆囊炎和胆总管囊肿）、13例类风湿性关节炎病例以及25名健康对照者的CIC中均未检测到阿米巴抗原。阿米巴抗原特异性CIC水平与肝脓肿数量或受累肝叶无关（p>0.05）。然而，肝下缘低于右肋缘5cm以上的患者抗原特异性CIC水平更高（p<0.01）。治疗完成后3至6个月内，抗原特异性CIC水平往往会下降或消失。（摘要截短至250字）
